Interview with Thierry Poiraud, General Manager, Menarini France
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Address: Menarini Building 1 rue du Jura 94633 Rungis Cedex BP 40528, France
Tel: 01 45 60 77 20
Web: http://www.menarini.fr/accueil/
Menarini started up its operations in Feb 1992 with a product portfolio acquired through an exchange of products with Sanofi. From this base, the affiliate ventured onto the French market and in 1993 it launched an original gel with analgesic and anti-inflammatory properties, and in a few months time it became the leader in this therapeutic class. Three innovative cardiovascular products have been launched successively in 2002 and 2004.
MENARINI, 1 Italian pharmaceutical group, today operates in over 100 countries. With over 2.6 billion euros in turnover, 12 500 employees, the Menarini Group is the 20th in European rankings and 36th in the world rankings.
France: 112.5 million euros in 2008; employs 600 (heavy growth in last 5 years, double # last 3 years and wants 150m euro for 2010)
Distribution of turnover: 30% Self-Medication – Ethical Drugs 70%
Commercial/Mkting autonomy for HQ
2 launches in 2009: cardiology, angina pectoris
Sports medicine and Rhumatology in France
Present in the most important therapeutic areas of greatest importance, including:
• Cardiovascular Products
• Gastro-intestinal Products
• Antibiotics / Respiratory System Products
• Diabetes
• Anti-inflammatory agents / Analgesics
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
Eric Bothorel, Deputy at the French Assemblée Nationale and responsible for the parliamentary group on data, knowledge & AI, provides an exclusive interview on France’s digitalization process. Bothorel describes France’s…
Dr. Julien Borowczyk, Secretary of the Social Affairs Commission at the French Assemblée Nationale, offers his insights on the upcoming changes to the French healthcare system. He walks our audience…
Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah…
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic…
Jacques Vernin, president of FACOPHAR Santé – the French association representing companies involved in the natural and herbal health space, explains its role and the future of the organization in…
Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since…
Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s health, its external growth strategy, notably through the acquisition of Finox Biotech in 2016, and…
Dominique Martin, CEO of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) provides a fascinating insight into the French process of authorizing drugs and medical…
Dr. Denis Comet, President of AFCRO (the French Association of CROs), talks about the evolution of the clinical research environment in France and the new government actions aimed at speeding…
See our Cookie Privacy Policy Here
